Trial Profile
A multicentre randomiSed controlled TRial of Intravenous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary) ; Methylprednisolone
- Indications Transverse myelitis
- Focus Therapeutic Use
- Acronyms STRIVE
- 11 May 2017 This trial has been completed in the United Kingdom (end date: 11 May 2016).
- 18 Jul 2016 Status changed from completed to discontinued.
- 12 Jul 2016 Status changed from active, no longer recruiting to completed.